Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Microtubule-targeting agents (MTAs) are crucial antimitotic drugs for cancer treatment.
• MTAs induce mitotic arrest via the spindle assembly checkpoint (SAC), leading to apoptosis.
• Limitations include toxicity, resistance, mitotic slippage, and failed apoptosis induction.

Purpose of the Study:

• To review second-generation antimitotic drugs targeting mitosis.
• To discuss strategies for improving anticancer efficacy by modulating SAC activity, mitotic slippage, and apoptosis.

Main Methods:

• Literature review of current and emerging antimitotic strategies.
• Analysis of mechanisms underlying mitotic arrest and cell death.
• Discussion of potential therapeutic interventions targeting mitosis.

Main Results:

• First-generation MTAs face challenges like resistance and toxicity.
• Second-generation antimitotics targeting kinases or other mitotic regulators have shown limited clinical success.
• Apoptosis emerges as a key determinant of antimitotic drug effectiveness.

Conclusions:

• Optimizing cancer therapy requires understanding and manipulating cell fate during mitotic arrest.
• Exploiting SAC activity, mitotic slippage, and apoptosis induction offers promising avenues for novel anticancer strategies.
• Future research should focus on combination therapies and personalized approaches to enhance antimitotic drug efficacy.